<DOC>
	<DOCNO>NCT01089088</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine hydrochloride cisplatin , work different way stop growth tumor cell , either kill cell stop dividing . Sunitinib malate may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Giving gemcitabine hydrochloride cisplatin together sunitinib malate may kill tumor cell . PURPOSE : This phase II trial study side effect give gemcitabine hydrochloride cisplatin together sunitinib malate see well work first-line therapy treat patient locally advance and/or metastatic transitional cell carcinoma urothelium .</brief_summary>
	<brief_title>Gemcitabine Hydrochloride , Cisplatin , Sunitinib Malate First-Line Therapy Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma Urothelium</brief_title>
	<detailed_description>OBJECTIVES : - To determine activity , safety , feasibility gemcitabine hydrochloride cisplatin combination sunitinib malate first-line therapy patient locally advance and/or metastatic transitional carcinoma urothelium . OUTLINE : This multicenter study . Patients receive gemcitabine hydrochloride IV 30 minute day 1 8 , cisplatin IV 3-4 hour day 1 , oral sunitinib malate daily day 2-15 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 6 month 1 year . Peer Reviewed Funded Endorsed Cancer Research UK</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm transitional cell carcinoma urothelium Pure mixed histology Upper low urinary tract Radiologically measurable , locally advanced and/or metastatic disease amenable curative treatment surgery radiotherapy meeting 1 follow criterion : T4b ( bladder ) T4 ( renal pelvis/ureter ) , N , M Any T , N23 , M Any T , N , M1 No urothelial cancer subsequent radical treatment consider view possibly cure disease No history CNS metastases PATIENT CHARACTERISTICS : WHO performance status 02 Life expectancy &gt; 3 month Absolute neutrophil count ≥ 1.5 x 10^9/L Platelet count ≥ 100 x 10^9/L Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT ALP ≤ 2.5 time ULN GFR ≥ 60 mL/min ( uncorrected surface area measure isotopic mean ) PT INR ≤ 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Fit receive cisplatincontaining combination chemotherapy No previous malignancy nonmelanoma skin cancer , carcinoma situ cervix , incidental localized prostate cancer No know HIV positivity chronic hepatitis B C infection No uncontrolled hypertension No symptomatic coronary artery disease , myocardial infarction within past 6 month , congestive cardiac failure ( NYHA class IIIIV disease ) , uncontrolled symptomatic cardiac arrhythmia No clinically significant bacterial fungal infection No concurrent grapefruit juice PRIOR CONCURRENT THERAPY : At least 1 month since prior radiotherapy radiotherapy involve 30 % total bone marrow volume At least 1 month since prior investigational drug No prior systemic therapy locally advance metastatic disease Patients receive prior neoadjuvant adjuvant chemotherapy urothelial cancer ( 4 course ) , complete least 6 month prior first documented disease progression , eligible No concurrent anticoagulant therapy warfarin unfractionated heparin Patients require anticoagulation may enter study successful conversion low molecular weight heparin No concurrent medication know adverse interaction sunitinib malate ( i.e. , strong CYP3A4 inhibitor inducer ) No prior concurrent live vaccine ( e.g. , measles , mumps , rubella , oral polio , bacille CalmetteGuérin [ BCG ] , yellow fever , varicella , TY21a typhoid vaccine )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>recurrent urethral cancer</keyword>
	<keyword>recurrent transitional cell cancer renal pelvis ureter</keyword>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>regional transitional cell cancer renal pelvis ureter</keyword>
	<keyword>posterior urethral cancer</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>anterior urethral cancer</keyword>
</DOC>